DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

21 Drugs in Development

21 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

21DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Cm-4620, 1713240-67-5, Zegocractin, Cm4620, Zegocractin [inn], Chembl4753998

Molecular Formula

C₁₉H₁₁ClF₃N₃O₃

Molecular Weight

421.8 g/mol

InChI Key

QQMKTHUGOQDEIL-UHFFFAOYSA-N

FDA UNII

564AW1RR37

Zegocractin is a calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential anti-inflammatory and protective activities. Upon administration, zegocractin targets, binds to and inhibits the calcium release-activated calcium channel protein 1 (Orai1), which forms the pore of CRAC, and is expressed on both parenchymal cells and immune cells. This prevents the transport of extracellular Ca2+ into the cell and inhibits the subsequent activation of Ca2+-mediated signaling and transcription of target genes. This may prevent Ca2+ entry-mediated cell death. It may also inhibit the proliferation of immune cells and prevents the release of various inflammatory cytokines in immune cells, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a). This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), mediate store operated Ca2+ entry (SOCE) and play a key role in calcium homeostasis. CRACs are overactivated in a variety of cell types, especially certain immune cells during inflammation, including T-lymphocytes, neutrophils and macrophages.

1 2D Structure

Zegocractin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide

2.1.2 InChI

InChI=1S/C19H11ClF3N3O3/c1-9-3-2-4-12(21)17(9)18(27)26-16-8-24-13(7-25-16)10-5-14-15(6-11(10)20)29-19(22,23)28-14/h2-8H,1H3,(H,25,26,27)

2.1.3 InChI Key

QQMKTHUGOQDEIL-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C(=CC=C1)F)C(=O)NC2=NC=C(N=C2)C3=CC4=C(C=C3Cl)OC(O4)(F)F

2.2 Other Identifiers

2.2.1 UNII

564AW1RR37

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Auxora

2. Cm 4620

3. Cm-128

4. Cm-4620

5. Cm128

6. Cm4620

7. N-(5-(6-chloro-2,2-difluorobenzo(d)(1,3)dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide

8. Zegocractin

2.3.2 Depositor-Supplied Synonyms

1. Cm-4620

2. 1713240-67-5

3. Zegocractin

4. Cm4620

5. Zegocractin [inn]

6. Chembl4753998

7. 564aw1rr37

8. N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide

9. Benzamide, N-(5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)-2-pyrazinyl)-2-fluoro-6-methyl-

10. N-(5-(6-chloro-2,2-difluorobenzo(d)(1,3)dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide

11. Cm 4620

12. Unii-564aw1rr37

13. Schembl18038390

14. Gtpl10087

15. Cm-4620 [who-dd]

16. Cm 4620 Pound>>cm4620

17. Dtxsid901337267

18. Bcp29536

19. Ex-a1898

20. Bdbm50575336

21. S6834

22. Compound I [wo2016138472a1]

23. Sb18686

24. Ac-35758

25. Bs-15636

26. Hy-101942

27. Cs-0022201

28. C73294

29. N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)-2-pyrazinyl]-2-fluoro-6-methylbenzamide

2.4 Create Date

2016-12-08

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₁ClF₃N₃O₃
Molecular Weight	421.8 g/mol
XLogP3	4.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	3
Exact Mass	421.0441034 g/mol
Monoisotopic Mass	421.0441034 g/mol
Topological Polar Surface Area	73.3 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	617
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1